An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease
oleh: Reda Ibrahim, John T Granton, Sanjay Mehta
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2006-01-01 |
Deskripsi
BACKGROUND: Bosentan has been shown to be a safe and efficacious treatment for idiopathic pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease. However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CHD).